Yu Wang1, Hong Liu2, Ben-Shu Zhang1, Jair C Soares3, Xiang Yang Zhang4. 1. Department of Neurology, Tianjin Medical University General Hospital, Tianjin, 300052, China. 2. Department of Neurology, Heping Hospital Affiliated to Changzhi Medical College, Shanxi Province, China. 3. Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston, TX, USA. 4. Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston, TX, USA; Beijing HuiLongGuan Hospital, Peking University, Beijing, China. Electronic address: zhangxy9@gmail.com.
Abstract
OBJECTIVE: Increasing evidence show that brain-derived neurotrophic factor (BDNF) plays a critical role in neuroplasticity in the hippocampus that is related to learning and memory. Parkinson disease (PD) is associated with impairment of cognitive function that may evolve from decreased BDNF. The aim of the present study was to examine the association of BDNF with cognitive impairment in PD. METHODS: We compared 97 PD patients to 102 healthy controls on serum BDNF and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Hoehn-Yahr staging test was used to assess motor abilities. RESULTS: Serum BDNF levels were significantly lower in PD patients than in healthy controls (p < 0.01). Cognitive performance shown on the RBANS total and all of its five index scores were significantly lower in PD patients than normal controls (all p < 0.05). For the patients only, BDNF was positively associated with all five index and total scores of RBANS. CONCLUSIONS: Our findings suggest extensive cognitive impairments and decreased BDNF in PD patients. Moreover, decreased BDNF is associated with cognitive deficits of Parkinson's disease.
OBJECTIVE: Increasing evidence show that brain-derived neurotrophic factor (BDNF) plays a critical role in neuroplasticity in the hippocampus that is related to learning and memory. Parkinson disease (PD) is associated with impairment of cognitive function that may evolve from decreased BDNF. The aim of the present study was to examine the association of BDNF with cognitive impairment in PD. METHODS: We compared 97 PDpatients to 102 healthy controls on serum BDNF and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Hoehn-Yahr staging test was used to assess motor abilities. RESULTS: Serum BDNF levels were significantly lower in PDpatients than in healthy controls (p < 0.01). Cognitive performance shown on the RBANS total and all of its five index scores were significantly lower in PDpatients than normal controls (all p < 0.05). For the patients only, BDNF was positively associated with all five index and total scores of RBANS. CONCLUSIONS: Our findings suggest extensive cognitive impairments and decreased BDNF in PDpatients. Moreover, decreased BDNF is associated with cognitive deficits of Parkinson's disease.
Authors: Roberta Oliveira da Costa; Carlos Vinicius Jataí Gadelha-Filho; Ayane Edwiges Moura da Costa; Mariana Lima Feitosa; Dayane Pessoa de Araújo; Jalles Dantas de Lucena; Pedro Everson Alexandre de Aquino; Francisco Arnaldo Viana Lima; Kelly Rose Tavares Neves; Glauce Socorro de Barros Viana Journal: Oxid Med Cell Longev Date: 2017-06-21 Impact factor: 6.543
Authors: Smijin K Soman; David Tingle; Raul Y Dagda; Mariana Torres; Marisela Dagda; Ruben K Dagda Journal: J Neurosci Res Date: 2021-05-27 Impact factor: 4.433